English
简体中文
Total: £ 56.28
Published Date: 2024-12-04 | Pages: 105 | Tables: 181 | Medical Care
The global market for Neurodegenerative Diseases Therapeutics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Diseases Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Neurodegenerative Diseases Therapeutics by region & country, by Type, and by Application.
The Neurodegenerative Diseases Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Diseases Therapeutics.
Market Segmentation
By Company
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
Segment by Type:
Multiple Sclerosis Therapeutics
Alzheimer's Disease Therapeutics
Parkinson's Disease Therapeutics
Parkinson's Disease Therapeutics
Others
Segment by Application
Child
Aldult
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Neurodegenerative Diseases Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Neurodegenerative Diseases Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Neurodegenerative Diseases Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Market Overview
1.1 Neurodegenerative Diseases Therapeutics Product Introduction
1.2 Global Neurodegenerative Diseases Therapeutics Market Size Forecast
1.3 Neurodegenerative Diseases Therapeutics Market Trends & Drivers
1.3.1 Neurodegenerative Diseases Therapeutics Industry Trends
1.3.2 Neurodegenerative Diseases Therapeutics Market Drivers & Opportunity
1.3.3 Neurodegenerative Diseases Therapeutics Market Challenges
1.3.4 Neurodegenerative Diseases Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Neurodegenerative Diseases Therapeutics Players Revenue Ranking (2023)
2.2 Global Neurodegenerative Diseases Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Neurodegenerative Diseases Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Neurodegenerative Diseases Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Neurodegenerative Diseases Therapeutics
2.6 Neurodegenerative Diseases Therapeutics Market Competitive Analysis
2.6.1 Neurodegenerative Diseases Therapeutics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Neurodegenerative Diseases Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Multiple Sclerosis Therapeutics
3.1.2 Alzheimer's Disease Therapeutics
3.1.3 Parkinson's Disease Therapeutics
3.1.4 Parkinson's Disease Therapeutics
3.1.5 Others
3.2 Global Neurodegenerative Diseases Therapeutics Sales Value by Type
3.2.1 Global Neurodegenerative Diseases Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Neurodegenerative Diseases Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Neurodegenerative Diseases Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Child
4.1.2 Aldult
4.2 Global Neurodegenerative Diseases Therapeutics Sales Value by Application
4.2.1 Global Neurodegenerative Diseases Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Neurodegenerative Diseases Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Neurodegenerative Diseases Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Neurodegenerative Diseases Therapeutics Sales Value by Region
5.1.1 Global Neurodegenerative Diseases Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Neurodegenerative Diseases Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Neurodegenerative Diseases Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Neurodegenerative Diseases Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
5.2.2 North America Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
5.3.2 Europe Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
5.5.2 South America Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Neurodegenerative Diseases Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Neurodegenerative Diseases Therapeutics Sales Value
6.3 United States
6.3.1 United States Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
6.3.2 United States Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Neurodegenerative Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
6.4.2 Europe Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Neurodegenerative Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
6.5.2 China Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Neurodegenerative Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
6.6.2 Japan Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Neurodegenerative Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Neurodegenerative Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Neurodegenerative Diseases Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Neurodegenerative Diseases Therapeutics Sales Value, 2019-2030
6.9.2 India Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Neurodegenerative Diseases Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AB Science SA
7.1.1 AB Science SA Profile
7.1.2 AB Science SA Main Business
7.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.1.4 AB Science SA Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 AB Science SA Recent Developments
7.2 AbbVie Inc.
7.2.1 AbbVie Inc. Profile
7.2.2 AbbVie Inc. Main Business
7.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.2.4 AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 AbbVie Inc. Recent Developments
7.3 Acadia Pharmaceuticals Inc.
7.3.1 Acadia Pharmaceuticals Inc. Profile
7.3.2 Acadia Pharmaceuticals Inc. Main Business
7.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.3.4 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Biogen Inc. Recent Developments
7.4 Biogen Inc.
7.4.1 Biogen Inc. Profile
7.4.2 Biogen Inc. Main Business
7.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.4.4 Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Biogen Inc. Recent Developments
7.5 F. Hoffmann La Roche Ltd.
7.5.1 F. Hoffmann La Roche Ltd. Profile
7.5.2 F. Hoffmann La Roche Ltd. Main Business
7.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.5.4 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 F. Hoffmann La Roche Ltd. Recent Developments
7.6 H Lundbeck AS
7.6.1 H Lundbeck AS Profile
7.6.2 H Lundbeck AS Main Business
7.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.6.4 H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 H Lundbeck AS Recent Developments
7.7 Mitsubishi Chemical Holdings Corp.
7.7.1 Mitsubishi Chemical Holdings Corp. Profile
7.7.2 Mitsubishi Chemical Holdings Corp. Main Business
7.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.7.4 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Mitsubishi Chemical Holdings Corp. Recent Developments
7.8 Novartis AG
7.8.1 Novartis AG Profile
7.8.2 Novartis AG Main Business
7.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.8.4 Novartis AG Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Novartis AG Recent Developments
7.9 Sanofi
7.9.1 Sanofi Profile
7.9.2 Sanofi Main Business
7.9.3 Sanofi Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.9.4 Sanofi Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 Sanofi Recent Developments
7.10 Teva Pharmaceutical Industries Ltd
7.10.1 Teva Pharmaceutical Industries Ltd Profile
7.10.2 Teva Pharmaceutical Industries Ltd Main Business
7.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Products, Services and Solutions
7.10.4 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 Teva Pharmaceutical Industries Ltd Recent Developments
8 Industry Chain Analysis
8.1 Neurodegenerative Diseases Therapeutics Industrial Chain
8.2 Neurodegenerative Diseases Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Neurodegenerative Diseases Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Neurodegenerative Diseases Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Neurodegenerative Diseases Therapeutics Market Trends
Table 2. Neurodegenerative Diseases Therapeutics Market Drivers & Opportunity
Table 3. Neurodegenerative Diseases Therapeutics Market Challenges
Table 4. Neurodegenerative Diseases Therapeutics Market Restraints
Table 5. Global Neurodegenerative Diseases Therapeutics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Neurodegenerative Diseases Therapeutics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Neurodegenerative Diseases Therapeutics Product Type
Table 9. Key Companies Time to Begin Mass Production of Neurodegenerative Diseases Therapeutics
Table 10. Global Neurodegenerative Diseases Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Neurodegenerative Diseases Therapeutics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Neurodegenerative Diseases Therapeutics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Neurodegenerative Diseases Therapeutics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Neurodegenerative Diseases Therapeutics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Neurodegenerative Diseases Therapeutics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Neurodegenerative Diseases Therapeutics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Neurodegenerative Diseases Therapeutics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Neurodegenerative Diseases Therapeutics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Neurodegenerative Diseases Therapeutics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Neurodegenerative Diseases Therapeutics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Neurodegenerative Diseases Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Neurodegenerative Diseases Therapeutics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Neurodegenerative Diseases Therapeutics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Neurodegenerative Diseases Therapeutics Sales Value by Region (2019-2024) & (%)
Table 27. Global Neurodegenerative Diseases Therapeutics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Neurodegenerative Diseases Therapeutics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Neurodegenerative Diseases Therapeutics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Neurodegenerative Diseases Therapeutics Sales Value, (2025-2030) & (US$ Million)
Table 31. AB Science SA Basic Information List
Table 32. AB Science SA Description and Business Overview
Table 33. AB Science SA Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of AB Science SA (2019-2024)
Table 35. AB Science SA Recent Developments
Table 36. AbbVie Inc. Basic Information List
Table 37. AbbVie Inc. Description and Business Overview
Table 38. AbbVie Inc. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of AbbVie Inc. (2019-2024)
Table 40. AbbVie Inc. Recent Developments
Table 41. Acadia Pharmaceuticals Inc. Basic Information List
Table 42. Acadia Pharmaceuticals Inc. Description and Business Overview
Table 43. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of Acadia Pharmaceuticals Inc. (2019-2024)
Table 45. Acadia Pharmaceuticals Inc. Recent Developments
Table 46. Biogen Inc. Basic Information List
Table 47. Biogen Inc. Description and Business Overview
Table 48. Biogen Inc. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of Biogen Inc. (2019-2024)
Table 50. Biogen Inc. Recent Developments
Table 51. F. Hoffmann La Roche Ltd. Basic Information List
Table 52. F. Hoffmann La Roche Ltd. Description and Business Overview
Table 53. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of F. Hoffmann La Roche Ltd. (2019-2024)
Table 55. F. Hoffmann La Roche Ltd. Recent Developments
Table 56. H Lundbeck AS Basic Information List
Table 57. H Lundbeck AS Description and Business Overview
Table 58. H Lundbeck AS Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of H Lundbeck AS (2019-2024)
Table 60. H Lundbeck AS Recent Developments
Table 61. Mitsubishi Chemical Holdings Corp. Basic Information List
Table 62. Mitsubishi Chemical Holdings Corp. Description and Business Overview
Table 63. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of Mitsubishi Chemical Holdings Corp. (2019-2024)
Table 65. Mitsubishi Chemical Holdings Corp. Recent Developments
Table 66. Novartis AG Basic Information List
Table 67. Novartis AG Description and Business Overview
Table 68. Novartis AG Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of Novartis AG (2019-2024)
Table 70. Novartis AG Recent Developments
Table 71. Sanofi Basic Information List
Table 72. Sanofi Description and Business Overview
Table 73. Sanofi Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of Sanofi (2019-2024)
Table 75. Sanofi Recent Developments
Table 76. Teva Pharmaceutical Industries Ltd Basic Information List
Table 77. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 78. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Neurodegenerative Diseases Therapeutics Business of Teva Pharmaceutical Industries Ltd (2019-2024)
Table 80. Teva Pharmaceutical Industries Ltd Recent Developments
Table 81. Key Raw Materials Lists
Table 82. Raw Materials Key Suppliers Lists
Table 83. Neurodegenerative Diseases Therapeutics Downstream Customers
Table 84. Neurodegenerative Diseases Therapeutics Distributors List
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Neurodegenerative Diseases Therapeutics Product Picture
Figure 2. Global Neurodegenerative Diseases Therapeutics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Neurodegenerative Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 4. Neurodegenerative Diseases Therapeutics Report Years Considered
Figure 5. Global Neurodegenerative Diseases Therapeutics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2023
Figure 7. Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Multiple Sclerosis Therapeutics Picture
Figure 9. Alzheimer's Disease Therapeutics Picture
Figure 10. Parkinson's Disease Therapeutics Picture
Figure 11. Parkinson's Disease Therapeutics Picture
Figure 12. Others Picture
Figure 13. Global Neurodegenerative Diseases Therapeutics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Neurodegenerative Diseases Therapeutics Sales Value Market Share by Type, 2023 & 2030
Figure 15. Product Picture of Child
Figure 16. Product Picture of Aldult
Figure 17. Global Neurodegenerative Diseases Therapeutics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Neurodegenerative Diseases Therapeutics Sales Value Market Share by Application, 2023 & 2030
Figure 19. North America Neurodegenerative Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 20. North America Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 21. Europe Neurodegenerative Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 22. Europe Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 23. Asia Pacific Neurodegenerative Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 24. Asia Pacific Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 25. South America Neurodegenerative Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 26. South America Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 27. Middle East & Africa Neurodegenerative Diseases Therapeutics Sales Value (2019-2030) & (US$ Million)
Figure 28. Middle East & Africa Neurodegenerative Diseases Therapeutics Sales Value by Country (%), 2023 VS 2030
Figure 29. Key Countries/Regions Neurodegenerative Diseases Therapeutics Sales Value (%), (2019-2030)
Figure 30. United States Neurodegenerative Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 31. United States Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 32. United States Neurodegenerative Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 33. Europe Neurodegenerative Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 34. Europe Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 35. Europe Neurodegenerative Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 36. China Neurodegenerative Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 37. China Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 38. China Neurodegenerative Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 39. Japan Neurodegenerative Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 40. Japan Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 41. Japan Neurodegenerative Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 42. South Korea Neurodegenerative Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 43. South Korea Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 44. South Korea Neurodegenerative Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 45. Southeast Asia Neurodegenerative Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 46. Southeast Asia Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 47. Southeast Asia Neurodegenerative Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 48. India Neurodegenerative Diseases Therapeutics Sales Value, (2019-2030) & (US$ Million)
Figure 49. India Neurodegenerative Diseases Therapeutics Sales Value by Type (%), 2023 VS 2030
Figure 50. India Neurodegenerative Diseases Therapeutics Sales Value by Application (%), 2023 VS 2030
Figure 51. Neurodegenerative Diseases Therapeutics Industrial Chain
Figure 52. Neurodegenerative Diseases Therapeutics Manufacturing Cost Structure
Figure 53. Channels of Distribution (Direct Sales, and Distribution)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
